



GP. 1648
PATENT #12

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF MAILING

I hereby certify that this INFORMATION DISCLOSURE STATEMENT and documents submitted therewith are being deposited with the United States Postal Service as first class mail, postage prepaid thereon, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below.

Ariel Fletcher
Ariel Fletcher

6/9/2003
Date

Applicant:	Burton, et al.)	Group:	1648
Serial No.:	10/016,986)		
Filed:	December 12, 2001)	Examiner:	Unassigned
For:	HUMAN NEUTRALIZING MONOCLONAL ANTIBODIES TO HUMAN IMMUNODEFICIENCY VIRUS)	Our Ref.:	TSRI 313.2 Con. 1
)		

RECEIVED
JUN 16 2003
TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In recognition of its continuing duty to disclose pursuant to 37 CFR §1.56, Applicant hereby submits the present Information Disclosure Statement in compliance therewith.

Pursuant to 37 CFR §1.98(d), enclosed herewith is a copy of 1) the Information Disclosure Statement and 2) the accompanying PTO Form 1449 filed in the application 08/276,852 which refers to and also includes Information Disclosure Statements filed in other related applications. Application 08/276,852 was filed on July 18, 1994, and has issued as U.S. Patent No. 5,652,138, to which the present application is related by continuation. Also,

pursuant to 37 CFR §1.98(d), copies of the above references are not submitted herewith, as they are available in the related patent application 08/276,852 and other related applications.


Applicants understand that the interpretation given to each reference may differ from one individual to another. The PTO is therefore encouraged to independently examine the disclosed references. While the references provided in this Information Disclosure Statement may be material pursuant to 37 CFR §1.56, it shall not be construed to be an admission that the cited information is, or is considered to be, material to patentability unless specifically designated as such.

Applicants are filing the present statement pursuant to 37 CFR §1.97(b) insofar as this statement is being filed within three months of the filing of the application and/or before the mailing date of a first Office Action.

Also, in accordance with 37 CFR §1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or, that if made, any search was complete or exhaustive, or that no other material information as defined in 37 CFR §1.56 exists.

Respectfully submitted,

June 09, 2003
Date


Michael J. McCarthy, Reg. No. 46,910

THE SCRIPPS RESEARCH INSTITUTE
Office of Patent Counsel
10550 North Torrey Pines Road
Mail Drop TPC-8
La Jolla, CA 92037
(858) 784-2937



RECEIVED
JUN 16 2003
TECH CENTER 1600/2900

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF MAILING

I hereby certify that this INFORMATION DISCLOSURE STATEMENT and documents submitted therewith are being deposited with the United States Postal Service as first class mail, postage prepaid thereon, in an envelope addressed to: Hon. Commissioner of Patents and Trademarks, Washington, D.C. 20231, on the date indicated below.

Thomas Fitting
Thomas Fitting, Reg. No. 34,163

January 10, 1995
Date

Applicant :	Burton, et al.)	
Serial No. :	08/276,852)	Group Art Unit: Unknown
Filed :	July 18, 1994)	
For :	HUMAN NEUTRALIZING)	
	MONOCLONAL ANTIBODIES TO)	
	HUMAN IMMUNODEFICIENCY)	
	VIRUS)	Our Ref. TSRI 313.2
)	
)	
)	

INFORMATION DISCLOSURE STATEMENT

Hon. Commissioner
of Patents and Trademarks
Washington, D.C. 20231

Dear Sir:

In recognition of their continuing duty to disclose pursuant to 37 CFR 1.56, Applicants hereby submit the present Information Disclosure Statement and accompanying PTO Form 1449 in compliance therewith. Copies of the references cited therein are also enclosed.

The following references were cited in the application and are believed relevant for the reasons set forth in the specification:

1. Kang, et al., Proc. Natl. Acad. Sci. USA, 88:4363-4366 (1991)
2. Kang, et al., Proc. Natl. Acad. Sci. USA, 88:11120-11123-4366 (1991)

Kang, et al., Proc. Natl. Acad. Sci. USA, 88:4363-4366 (1991) describes the use of the filamentous phage coat protein membrane anchor domain cpVIII as a means for linking gene-product and gene during the assembly stage of filamentous phage replication and the use of this technology for the cloning and expression of antibodies. Kang, et al., Proc. Natl. Acad. Sci. USA, 88:11120-11123-4366 (1991) describes a method to increase the diversity of a filamentous phage-based combinatorial antibody library by shuffling of the heavy and light chain genes.

The following references were cited during the prosecution of related U.S. patent Application Serial No. 07/954,148, now abandoned, and are believed relevant for that reason:

1. Berkower, et al., J. Virol., 65: 5983-5990 (1991)
2. Brolden, et al., Immunology, 73: 371-376 (1991)
3. Burton, et al., PNAS, USA, 88: 10134-10137 (1991)
4. D'Souza, et al., AIDS, 1061-1070 (1991)
5. Gorny, et al., PNAS, USA, 88: 3238-3242 (1991)
6. Ho, et al., J. Virol., 65: 489-493 (1991)
7. Ho, et al., PNAS, USA, 88: 8949-8952 (1991)
8. Jackson, et al., Lancet, September 17, 1988, pp. 647-651
9. Kang, et al., PNAS, USA, 88: 6171-6175 (1991)
10. Karpas, et al., PNAS, USA, 87: 7613-7617 (1990)
11. Karwowska, et al., AIDS Res. and Hum. Retroviruses, 8: 1099-1106 (1992)
12. Laman, et al., J. Virol., 66: 1823-1831 (1992)
13. Linsley, et al., J. Virol., 62: 3695-3702 (1988)
14. McKeating, et al., AIDS, 3: 777-784 (1989)
15. Nara, et al., AIDS Res. and Hum. Retroviruses, 3: 283-302 (1987)
16. Nara, et al., FASEB J., 5: 2437-2455 (1991)
17. Posner, et al., J. Immunol., 146: 4325-4332 (1991)
18. Skinner, et al., J. Virol., 62: 4195-4200 (1988)
19. Steimer, et al., Science, 254: 105-108 (1991)

20. Takeda, et al., J. Clin Invest., 89: 1952-1957 (1992)
21. Thali, et al., J. Virol., 65: 6188-6193 (1991)
22. Tilley, et al., AIDS Res. and Hum. Retroviruses, 8: 461-467 (1992)
23. Tilley, et al., Res. Virol., 142: 247-259 (1991)
24. Wahlberg, et al., AIDS Res. and Hum. Retroviruses, 7: 983-990 (1991)

Pursuant to 37 CFR §1.98(d), copies of the references listed above are not submitted herewith, as they are available in the related U.S. patent Application Serial No. 07/954,148, relied upon for an earlier filing date. However, for the convenience of the Examiner, the references are listed above, and a copy of Information Disclosure Statement and PTO Form 1449 is enclosed.

The following references were cited in the Search Report of the PCT patent Application No. PCT/US 93/09328 corresponding to the above-referenced U.S. application and are believed relevant for that reason:

1. Burton, et al., Proc. Natl. Acad. Sci., USA, 88: 10134-10137 (1991)
2. Ho, et al., J. Virol., 65: 489-493 (1991)
3. Gorny, et al., Proc. Natl. Acad. Sci., USA, 88: 3238-3242 (1991)
4. Posner, et al., J. Immunol., 146: 4325-4332 (1991)
5. Tilley, et al., Res. Virol., 142: 247-259 (1991)
6. Karwowska, et al., Aids Res. and Hum. Retroviruses, 8: 1099-1106 (1992)

Pursuant to 37 CFR §1.98(d), copies of the following references are not submitted herewith, as they are available in the

PCT patent Application PCT/US 93/09328, relied upon for an earlier filing date. However, for the convenience of the Examiner, a copy of the Search Report is enclosed.

Additional relevant references have not been cited during the prosecution of copending, related US patent Application Serial No. 08/178,302.

Applicants understand that the interpretation given to each reference may differ from one individual to another. The PTO is therefore encouraged to independently examine the disclosed references. While the references provided in this Information Disclosure Statement may be material pursuant to 37 CFR 1.56, it shall not be construed to be an admission that the cited information is, or is considered to be, material to patentability unless specifically designated as such.

Applicants are filing the present statement pursuant to 37 CFR 1.97 (b) insofar as this statement is being filed before the mailing date of a first Office Action.

Also in accordance with 37 CFR 1.97 (g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or, that if made, any search was complete or exhaustive, or that no other material information as defined in 37 CFR 1.56 exists.

Respectfully submitted,

Dated: 1/10/95 By: Thomas Fitting
Thomas Fitting
Registration No. 34,163
THE SCRIPPS RESEARCH INSTITUTE
Office of Patent Counsel
10666 N. Torrey Pines Road
Mail Drop TPC-8
La Jolla, CA 92037
(619) 554-2937



FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

ATTY DOCKET NO.
TSRI 313.2

SERIAL NO.
08/276,852

APPLICANT
Burton, et al.

FILING DATE
July 18, 1994

GROUP
Unknown

JUN 16 2003
RECEIVED
TECH CENTER 1600/2300

U.S. PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	FILING DATE

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

1 Kang, et al., Proc. Natl. Acad. Sci. USA, 88:4363-4366 (1991)

2 Kang, et al., Proc. Natl. Acad. Sci. USA, 88:11120-11123 (1991)

3

4

5

6

7

8

9

10

11

12

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF MAILING

I hereby certify that this INFORMATION DISCLOSURE STATEMENT and the documents referred to as enclosed therein are being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231 on the date written below.

Thomas Fitting
Thomas Fitting, Reg. No. 34,163

October 29, 1992

Date of Deposit

Applicant:	Burton, et al.)
)
Serial No:	07/954,148) Group Art
) Unit: Unassigned
Filed:	September 30, 1992)
)
For:	HUMAN NEUTRALIZING MONOCLONAL)
	ANTIBODIES TO HUMAN)
	IMMUNODEFICIENCY VIRUS)
)
Examiner:	Unassigned) Our Ref. No. SCR 1134P
) October 29, 1992

INFORMATION DISCLOSURE STATEMENT

Honorable Commissioner of
Patents and Trademarks
Washington, D.C. 20231

Sir:

In recognition of their continuing duty to disclose pursuant to 37 CFR 1.56, Applicants hereby submit the present Information Disclosure Statement and accompanying PTO Form 1449 in compliance therewith. Copies of the references cited therein are also enclosed.

Applicants understand that the interpretation given to each reference may differ from one individual to another. The PTO is therefore encouraged to independently examine the disclosed references. While the references provided in this Information Disclosure Statement may be material pursuant to 37 CFR 1.56, it shall not be construed to be an admission that the cited information is, or is considered to be, material to patentability unless specifically designated as such.

RECEIVED
JUN 16 2003
TECH CENTER 1600/2900

Applicants are filing the present statement pursuant to 37 CFR 1.97 (b) insofar as this statement is being filed before the mailing date of a first Office Action.

Also, in accordance with 37 CFR 1.97 (g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or, that if made, any search was complete or exhaustive, or that no other material information as defined in 37 CFR 1.56 exists.

Respectfully submitted,

Dated: 10/27/92

By Thomas Fitting

Thomas Fitting
THE SCRIPPS RESEARCH INSTITUTE
Office of Patent Counsel
10666 N. Torrey Pines Road
Mail Drop TPC-8
La Jolla, CA 92037
(619) 554-2937

LB\c:\pto\newin.dis

INFORMATION DISCLOSURE
STATEMENT BY APPLICANTATTY DOCKET NO.
TSRI 313.2 Con 1SERIAL NO.
10/016,986APPLICANT
Burton, Barbas, LernerFILING DATE
12/12/2001

GROUP

U.S. PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
1		5,652,138	07/29/97	Burton, et al.	435	252.33	
2		5,804,440	09/08/98	Burton, et al.	435	339.1	

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

1	Barbas, et al. <i>J. Mol. Bio.</i> , 230: 812-823 (1993)
2	Barbas, et al. <i>PNAS USA</i> , 89(19): 9339-9343 (1992)
3	Barbas, et al. <i>PNAS USA</i> , 91: 3809-3813 (1994)
4	Bender, et al. <i>Human Antibodies and Hybridomas</i> , 4: 74-79 (1993)
5	Buchacher, et al. <i>Vaccines</i> 92: 191-195 (1992)
6	Burton, et al. <i>Science</i> , 266: 1024-1027 (1994)
7	Fahey, et al. <i>Clin. Exp. Immunol.</i> , 88: 1-5 (1992)
8	Fox, JL. <i>Bio/Technology</i> , 12: 128 (1994)
9	Krust, et al. <i>AIDS</i> , 2(1): 17-24 (1988)
10	Moore, et al. <i>J. Virology</i> , 69(1): 101-109 (1995)
11	Roben, et al. <i>J. Virology</i> , 68(8): 4821-4828 (1994)
12	Zebedee, et al. <i>PNAS USA</i> , 89(8): 3175-3179 (1992)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

RECEIVED
TECH CENTER 1600/2000
JUN 16 2003

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.
LB\c:\forms\scr11341.449

AMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.
C:\FORMS\SCR11342.449

AMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if it is not considered. Include copy of this form with next communication to Applicant.